U.S. Markets open in 3 hrs 14 mins

Bayer Aktiengesellschaft (BAYZF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
50.33+0.13 (+0.26%)
At close: 3:29PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close50.20
Open51.02
Bid0.00 x 0
Ask0.00 x 0
Day's Range50.33 - 51.02
52 Week Range45.97 - 86.35
Volume6,221
Avg. Volume10,664
Market Cap49.533B
Beta (5Y Monthly)1.25
PE Ratio (TTM)6.82
EPS (TTM)7.38
Earnings DateN/A
Forward Dividend & Yield3.07 (6.10%)
Ex-Dividend DateApr 29, 2020
1y Target EstN/A
  • Bayer to Acquire a Lead Position in America's Gene Therapy Space
    Motley Fool

    Bayer to Acquire a Lead Position in America's Gene Therapy Space

    The world's largest pharmaceuticals and chemicals conglomerate took another big step into the gene therapy arena on Monday. Bayer (OTC: BAYRY) has agreed to acquire Asklepios BioPharmaceutical, a privately held U.S. company more commonly known as AskBio. Bayer will pay $2 billion in cash upfront for AskBio plus up to $2 billion in success-dependent milestone payments.

  • Barrons.com

    Bayer Is the Latest Drug Giant Betting on Gene Therapy With a $4 Billion U.S. Acquisition

    Bayer is entering the gene therapy market, with an acquisition of a U.S.-based pioneer in the field, AskBio, worth up to $4 billion. Shares in the German pharmaceutical giant rose nearly 2% in Frankfurt trading. Gene therapy is a medical approach to treating and preventing diseases using genes instead of traditional drugs, similar to cell therapy.

  • Bayer Acquires AskBio For $4B To Strengthen Its Gene Therapy Platform
    Benzinga

    Bayer Acquires AskBio For $4B To Strengthen Its Gene Therapy Platform

    German pharma and life sciences company Bayer AG (OTC: BAYRY) has acquired U.S.-based gene therapy biotech company Asklepios Biopharmaceutical Inc (AskBio) in a deal valued up to $4 billion.The purchase price of $2 billion will be paid upfront, and the remaining half will be payable in success-based milestone payments. Approximately 75% of the milestone payment amount will be due in the next five years.The agreement is expected to close in the fourth quarter of 2020, subject to regulatory approval.What Happened: The acquisition will give Bayer rights for AskBio's intellectual properties, including a functional Contract Development and Manufacturing Organization (CDMO), as well as AskBio's cutting edge adeno-associated virus-based gene therapies, technology, and manufacturing platforms.Bayer has engaged Credit Suisse Group AG (NYSE: CS) as a financial advisor, whereas AskBio has JPMorgan Chase & Co (NYSE: JPM) as the financial advisor.AskBio will continue to function as an independent entity on an arms-length basis after completing the acquisition transaction.Why Does It Matter: AskBio develops gene therapies for neuromuscular, central nervous system, cardiovascular and metabolic diseases.According to Bloomberg, with some patents for key therapies set to expire, the biotech acquisition could support Bayer's cell and gene therapy treatments.In 2019, Bayer acquired 100% interest in engineered cell therapy company BlueRock Therapeutics for $600 million. BlueRock was established as a joint venture in 2016, in partnership with healthcare investment firm Versant Ventures.Price Action: On Friday, BAYRY shares closed at $12.50 with a marginal 0.16% gain.Image Courtesy: NIH Image GallerySee more from Benzinga * Click here for options trades from Benzinga * Samsung Shares Surge As Jay Y Lee Set To Take Charge After Father's Death * SAP Lowers 2020 Guidance As Revenue Falls In Q3(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.